C4 Therapeutics, Inc. Revenue Breakdown
No Revenue Breakdown for CCCC on this site yet.
- 2025-12-31: Others Not split by product in the filing$35.95M100.00%; Total revenue $35.95M.
- 2024-12-31: Others Not split by product in the filing$35.58M100.00%; Total revenue $35.58M.
- 2023-12-31: Others Not split by product in the filing$20.76M100.00%; Total revenue $20.76M.
- 2022-12-31: Others Not split by product in the filing$31.10M100.00%; Total revenue $31.10M.
Source checked: the stored Revenue Breakdown page for CCCC.
Revenue by product
Each year (12 month)
| Fiscal year end | Others | Total revenue |
|---|---|---|
| 2025-12-31 | Not split by product in the filing $35.95M 100.00% | $35.95M |
| 2024-12-31 | Not split by product in the filing $35.58M 100.00% | $35.58M |
| 2023-12-31 | Not split by product in the filing $20.76M 100.00% | $20.76M |
| 2022-12-31 | Not split by product in the filing $31.10M 100.00% | $31.10M |
| 2021-12-31 | Not split by product in the filing $45.78M 100.00% | $45.78M |
Each quarter (3 month)
| Quarter end | Others | Total revenue |
|---|---|---|
| 2026-06-30 | Not split by product $6.64M 100.00% | $6.64M |
| 2026-03-31 | Not split by product $6.15M 100.00% | $6.15M |
| 2025-12-31 | Not split by product $11.02M 100.00% | $11.02M |
| 2025-09-30 | Not split by product $11.23M 100.00% | $11.23M |
| 2025-06-30 | Not split by product $6.46M 100.00% | $6.46M |
| 2025-03-31 | Not split by product $7.24M 100.00% | $7.24M |
| 2024-12-31 | Not split by product $5.18M 100.00% | $5.18M |
| 2024-09-30 | Not split by product $15.36M 100.00% | $15.36M |
| 2024-06-30 | Not split by product $12.01M 100.00% | $12.01M |
| 2024-03-31 | Not split by product $3.04M 100.00% | $3.04M |
| 2023-12-31 | Not split by product $3.26M 100.00% | $3.26M |
| 2023-09-30 | Not split by product $11.07M 100.00% | $11.07M |
| 2023-06-30 | Not split by product $2.66M 100.00% | $2.66M |
| 2023-03-31 | Not split by product $3.76M 100.00% | $3.76M |
| 2022-12-31 | Not split by product $2.85M 100.00% | $2.85M |
| 2022-09-30 | Not split by product $6.75M 100.00% | $6.75M |
| 2022-06-30 | Not split by product $13.83M 100.00% | $13.83M |
| 2022-03-31 | Not split by product $7.65M 100.00% | $7.65M |
| 2021-12-31 | Not split by product $20.08M 100.00% | $20.08M |
| 2021-09-30 | Not split by product $8.50M 100.00% | $8.50M |
| 2021-06-30 | Not split by product $9.78M 100.00% | $9.78M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |